VC-backed Crinetics Pharmaceuticals debuts IPO
San Diego-based Crinetics Pharmaceuticals, a drug developer focused on rare endocrine diseases and endocrine-related tumors, has raised $102 million for its IPO after pricing its 6 million shares at $17 per share. The stock began trading July 18, 2018 on the NASDAQ under the ticker symbol "CRNX." J.P. Morgan Securities LLC, Leerink Partners LLC and Piper Jaffray & Co are the lead underwriters. Crinetics' pre-IPO backers include Versant Ventures, 5AM Ventures and Vivo Capital.
18 July 2018•3 mins read
